ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...
Insulet has reported results from two clinical studies, STRIVE and EVOLUTION 3, assessing its upcoming Omnipod 6 automated insulin delivery (AID) system and a fully closed-loop (FCL) solution for ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has shared new ...
STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using ...
Results from the STRIVE pivotal trial and the EVOLUTION 3 feasibility study, presented at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans, demonstrate meaningful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results